Tag: Alzheimer’s


Neuralink and Synchron: The Billionaire Battle of the Brain Chip

April 30, 2024

Via: Camila Mendes

Elon Musk. Jeff Bezos. Bill Gates. These three men have a lot in common. They’re all tech founders who have disrupted their respective industries and cemented their place in the annals of history for their global (and extra-terrestrial) dominance. Between […]

Biotech, Industry

For neurological disease, solving measurement is the first and biggest hurdle to re-imagining treatment

July 13, 2022

Via: Pharmaphorum

“Your primary endpoint is now down to a subjective measure in different trial centres, perhaps done by different people with different subjectivity,” says David van Zuydam, CEO of Head Therapeutics. “And now we’re going to determine whether this drug is […]


AbbVie cuts Alzheimer’s alliance with Alector in half

July 11, 2022

Via: Pharmaphorum

AbbVie first bought in to the programme with a $205 million upfront payment five years ago, attracted by the potential to use checkpoint inhibitors to try to reproduce in neurology the sometimes stunning results achieved with the class in oncology. […]

Biotech, Cell and Gene Therapy, Industry, News

Biogen puts down massive $350M upfront for Sangamo preclinical assets

February 28, 2020

Via: FierceBiotech

A year ago, Sangamo’s shares sank after it posted lackluster data for its genome-editing therapy; 12 months down the line, and it’s a complete reversal for the biotech as Biogen lays down a major upfront and biobucks pact for several […]